As of September 30, 2025, Cingulate (CING) had approximately $6.1 million in cash and cash equivalents, a $6.1 million decrease from December 31, 2024. The Company expects its cash will satisfy its capital needs into the second quarter of 2026 under the current business plan. To advance the commercialization efforts through the May 31, 2026 PDUFA date for CTx-1301, the Company will need to raise approximately $7.0 million of additional capital. As of September 30, 2025, Cingulate had approximately $1.6 million in working capital, a decrease of $6.1 million as compared to $7.7 million as of December 31, 2024.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Inc Signs Note Purchase Agreement with Avondale
- Cingulate names Downey as CCO to lead launch prep for CTx-1301
- Cingulate presents Phase 3 results for CTx-1301, met primary endpoint
- Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success
- Cingulate price target raised to $17 from $10 at Roth Capital